Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by fouremmon Mar 18, 2015 11:11pm
179 Views
Post# 23536904

RE:RE:RE:RE:RE:RE:RE:RE:RE:RVX Analyst Report, CDN$5.85 target http://www.resverlo

RE:RE:RE:RE:RE:RE:RE:RE:RE:RVX Analyst Report, CDN$5.85 target http://www.resverloAgree with you 100% and a lot of people forget that MACE was a pre-specified secondary endpoint in ASSURE but it does not change the fact that the market kills you and holds it against you for a long time when you miss a primary endpoint. Even when ph2 are still learning trials.  What is interesting is that I was told that RVX wanted to publish post hoc MACE numbers after SUSTAIN but were discouraged from doing so for fear that the numbers "were so good they were a fluke" (that is a direct quote).  Wouldn't we be in a different place if MACE had been the primary endpoint of ASSURE.  Mind you many of us probably wouldn't have as many shares as we do now.  Hopefully it all works out well.
Bullboard Posts